Investigation into Integer Holdings' Shareholder Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 47 minutes ago
0mins
Should l Buy ITGR?
Source: Newsfilter
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers of Integer Holdings breached their fiduciary duties, with allegations that the company significantly overstated its competitive position in the EP manufacturing market.
- Sales Decline Concealment: Despite Integer's claims of strong visibility into customer demand, the company has been experiencing a sustained deterioration in sales related to two of its EP devices, raising concerns about its business outlook.
- Misleading Statements: Integer mischaracterized its EP devices as long-term growth drivers for its C&V segment, yet these positive business statements were materially false and misleading during all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorney promptly to enforce their rights within a limited timeframe, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 85.620
Low
75.00
Averages
86.25
High
95.00
Current: 85.620
Low
75.00
Averages
86.25
High
95.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Integer Holdings' Shareholder Lawsuit
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers of Integer Holdings breached their fiduciary duties, with allegations that the company significantly overstated its competitive position in the EP manufacturing market.
- Sales Decline Concealment: Despite Integer's claims of strong visibility into customer demand, the company has been experiencing a sustained deterioration in sales related to two of its EP devices, raising concerns about its business outlook.
- Misleading Statements: Integer mischaracterized its EP devices as long-term growth drivers for its C&V segment, yet these positive business statements were materially false and misleading during all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorney promptly to enforce their rights within a limited timeframe, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
See More
Investigation into Integer Holdings' Shareholder Lawsuit
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers of Integer Holdings breached their fiduciary duties, with allegations that the company significantly overstated its competitive position in the EP manufacturing market.
- Sales Decline Concealment: Despite Integer's claims of strong visibility into customer demand, the company has been experiencing a sustained deterioration in sales related to two of its EP devices, raising concerns about its market performance.
- Misleading Growth Drivers: Integer mischaracterized its EP devices as long-term growth drivers for its C&V segment, a claim that lacks a reasonable basis and misled investors regarding the company's prospects.
- Legal Consequences Warning: Shareholders are urged to contact Kuehn Law promptly to enforce their rights, as there may be time limitations, and participation in the lawsuit contributes to the integrity of financial markets.
See More
Integer Holdings Board Chair Transition Announced
- Board Chair Transition: Integer Holdings Corporation announced that current independent Chair Pamela G. Bailey will not seek re-election, with the transition set for the Annual Meeting on May 20, 2026, indicating a significant governance shift for the company.
- New Chair Background: Current director Donald J. Spence will assume the chair position; having served on the board since 2016, he has been pivotal in guiding the company's strategic direction, and is expected to continue advancing long-term value creation strategies.
- Leadership Confidence: Bailey expressed confidence in Spence's leadership, believing he will work closely with CEO Payman Khales and the executive team to further support the company's growth and strategic success, reflecting a positive outlook for future developments.
- Strategic Positioning: Spence emphasized Integer's leading position in the medical device contract development and manufacturing sector, committing to continue driving value creation in the cardiovascular, neuromodulation, and cardiac rhythm management markets to ensure long-term shareholder benefits.
See More
Integer Holdings VP Sells 825 Shares Amid Ongoing Liquidity Management
- Executive Trading Overview: On March 13, 2026, Integer Holdings' VP Tom Thomas sold 825 shares of common stock in an open-market transaction valued at approximately $70,000, leaving him with 4,381 shares worth about $364,000, indicating a routine liquidity management strategy rather than a shift in conviction.
- Transaction Proportion Analysis: This sale represented 15.85% of Thomas's direct holdings, reflecting a consistent trading pattern over the past year that aligns with liquidity management rather than signaling negative sentiment about the company's future.
- Company Financial Performance: Integer Holdings reported $1.85 billion in revenue for fiscal year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, driven primarily by strong growth in its cardio and vascular segments, despite a 28% decline in stock price over the past year.
- Market Outlook Consideration: While the insider sale appears routine, investors are more focused on whether Integer can convert consistent revenue growth into sustained margin expansion and balance sheet improvement, which will likely have a more significant impact on the company's future market performance.
See More
Integer Holdings Insider Sells Shares
- Insider Stock Sale: On March 13, 2026, Tom Thomas, VP of Integer Holdings, sold 825 shares of common stock for a total transaction value of $70,000, representing 15.85% of his direct holdings, indicating a liquidity management action by the executive.
- Transaction Context: The sale was executed via direct ownership without involving any indirect entities or derivative securities, suggesting that this move is routine rather than a shift in confidence, despite the company's stock declining about 28% over the past year.
- Financial Performance Overview: Integer reported approximately $1.85 billion in sales for full-year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, primarily driven by growth in its cardio and vascular segment through new product ramps and acquisitions.
- Future Outlook Challenges: Despite consistent revenue growth, the company's leverage remains elevated near 3.0 times EBITDA, with debt increasing to $1.185 billion, prompting investors to consider whether Integer can translate revenue growth into sustained margin expansion and balance sheet improvement.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes' motion to dismiss, allowing the securities fraud class action to proceed, indicating serious consideration of investor allegations that could lead to significant financial liabilities for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may undermine investor confidence.
- Shareholder Rights Protection: Shareholders who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting legal avenues available for affected investors to potentially reclaim losses.
- Potential Market Impact: As the lawsuit progresses and may result in liability for the company, investor confidence in ASP Isotopes could wane, negatively impacting its stock price and reflecting market concerns over corporate governance and transparency.
See More
Investigation into Integer Holdings' Shareholder Lawsuit
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers of Integer Holdings breached their fiduciary duties, with allegations that the company significantly overstated its competitive position in the EP manufacturing market.
- Sales Decline Concealment: Despite Integer's claims of strong visibility into customer demand, the company has been experiencing a sustained deterioration in sales related to two of its EP devices, raising concerns about its business outlook.
- Misleading Statements: Integer mischaracterized its EP devices as long-term growth drivers for its C&V segment, yet these positive business statements were materially false and misleading during all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorney promptly to enforce their rights within a limited timeframe, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
See More
Investigation into Integer Holdings' Shareholder Lawsuit
- Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether certain officers of Integer Holdings breached their fiduciary duties, with allegations that the company significantly overstated its competitive position in the EP manufacturing market.
- Sales Decline Concealment: Despite Integer's claims of strong visibility into customer demand, the company has been experiencing a sustained deterioration in sales related to two of its EP devices, raising concerns about its market performance.
- Misleading Growth Drivers: Integer mischaracterized its EP devices as long-term growth drivers for its C&V segment, a claim that lacks a reasonable basis and misled investors regarding the company's prospects.
- Legal Consequences Warning: Shareholders are urged to contact Kuehn Law promptly to enforce their rights, as there may be time limitations, and participation in the lawsuit contributes to the integrity of financial markets.
See More
Integer Holdings Board Chair Transition Announced
- Board Chair Transition: Integer Holdings Corporation announced that current independent Chair Pamela G. Bailey will not seek re-election, with the transition set for the Annual Meeting on May 20, 2026, indicating a significant governance shift for the company.
- New Chair Background: Current director Donald J. Spence will assume the chair position; having served on the board since 2016, he has been pivotal in guiding the company's strategic direction, and is expected to continue advancing long-term value creation strategies.
- Leadership Confidence: Bailey expressed confidence in Spence's leadership, believing he will work closely with CEO Payman Khales and the executive team to further support the company's growth and strategic success, reflecting a positive outlook for future developments.
- Strategic Positioning: Spence emphasized Integer's leading position in the medical device contract development and manufacturing sector, committing to continue driving value creation in the cardiovascular, neuromodulation, and cardiac rhythm management markets to ensure long-term shareholder benefits.
See More
Integer Holdings VP Sells 825 Shares Amid Ongoing Liquidity Management
- Executive Trading Overview: On March 13, 2026, Integer Holdings' VP Tom Thomas sold 825 shares of common stock in an open-market transaction valued at approximately $70,000, leaving him with 4,381 shares worth about $364,000, indicating a routine liquidity management strategy rather than a shift in conviction.
- Transaction Proportion Analysis: This sale represented 15.85% of Thomas's direct holdings, reflecting a consistent trading pattern over the past year that aligns with liquidity management rather than signaling negative sentiment about the company's future.
- Company Financial Performance: Integer Holdings reported $1.85 billion in revenue for fiscal year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, driven primarily by strong growth in its cardio and vascular segments, despite a 28% decline in stock price over the past year.
- Market Outlook Consideration: While the insider sale appears routine, investors are more focused on whether Integer can convert consistent revenue growth into sustained margin expansion and balance sheet improvement, which will likely have a more significant impact on the company's future market performance.
See More
Integer Holdings Insider Sells Shares
- Insider Stock Sale: On March 13, 2026, Tom Thomas, VP of Integer Holdings, sold 825 shares of common stock for a total transaction value of $70,000, representing 15.85% of his direct holdings, indicating a liquidity management action by the executive.
- Transaction Context: The sale was executed via direct ownership without involving any indirect entities or derivative securities, suggesting that this move is routine rather than a shift in confidence, despite the company's stock declining about 28% over the past year.
- Financial Performance Overview: Integer reported approximately $1.85 billion in sales for full-year 2025, an 8% year-over-year increase, with adjusted operating income rising 13% and adjusted EPS climbing 21%, primarily driven by growth in its cardio and vascular segment through new product ramps and acquisitions.
- Future Outlook Challenges: Despite consistent revenue growth, the company's leverage remains elevated near 3.0 times EBITDA, with debt increasing to $1.185 billion, prompting investors to consider whether Integer can translate revenue growth into sustained margin expansion and balance sheet improvement.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes' motion to dismiss, allowing the securities fraud class action to proceed, indicating serious consideration of investor allegations that could lead to significant financial liabilities for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may undermine investor confidence.
- Shareholder Rights Protection: Shareholders who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting legal avenues available for affected investors to potentially reclaim losses.
- Potential Market Impact: As the lawsuit progresses and may result in liability for the company, investor confidence in ASP Isotopes could wane, negatively impacting its stock price and reflecting market concerns over corporate governance and transparency.
See More
